Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Garima

      Articles By : Garima

      Amgen to buy Nuevolution for $167 million

      Amgen to buy Nuevolution for $167 million

      Garima26 May 2019 9:10 AM IST
      Amgen, which is grappling with competition to its new migraine treatment Aimovig and cholesterol fighter Repatha, said it had collaborated with...
      GSK, Pfizer gets CCI approval for consumer healthcare JV formation

      GSK, Pfizer gets CCI approval for consumer healthcare JV formation

      Garima25 May 2019 9:45 AM IST
      After the deal, GSK will have a majority controlling equity interest of 68 per cent in the combined consumer healthcare business, while Pfizer will...
      Novartis India Q4 profit falls 26 percent to Rs 20 crore

      Novartis India Q4 profit falls 26 percent to Rs 20 crore

      Garima25 May 2019 9:30 AM IST
      Novartis India's board has recommended a dividend of 200 per cent (Rs 10 per equity share of Rs 5 each) for the year ended March 31, 2019.New Delhi:...
      Cipla to acquire 26 percent stake in AMP Solar Power Systems

      Cipla to acquire 26 percent stake in AMP Solar Power Systems

      Garima24 May 2019 9:30 AM IST
      Cipla will acquire and maintain 26 per cent stake on a fully diluted basis in AMPSolar throughout the term of the power purchase agreement, share...
      Torrent Pharma posts Q4 net loss of Rs 152 crore

      Torrent Pharma posts Q4 net loss of Rs 152 crore

      Garima24 May 2019 9:15 AM IST
      The company had posted a net profit of Rs 228 crore for the corresponding period of the previous fiscal, Torrent Pharma said in a filing to the...
      Cipla Q4 net profit jumps 133 pc at Rs 357.68 crore; plans fundraising of Rs 6000 crore

      Cipla Q4 net profit jumps 133 pc at Rs 357.68 crore; plans fundraising of Rs 6000 crore

      Garima23 May 2019 9:15 AM IST
      Cipla has also decided to raise funds of up to Rs 6,000 crore.New Delhi: Drug major Cipla Wednesday reported over two-fold jump in consolidated net...
      Varian to acquire Cancer Treatment Services International for Rs 1980 crore

      Varian to acquire Cancer Treatment Services International for Rs 1980 crore

      Garima22 May 2019 9:30 AM IST
      These fast-growing offerings will allow Varian to expand its solutions while helping to support the continued growth trajectory of the company’s...
      Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash

      Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash

      Garima22 May 2019 9:00 AM IST
      Merck Inc's lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.New Delhi: Merck & Co Inc said on...
      GSK Pharma Q4 net profit rises 16.56 percent to Rs 123 crore

      GSK Pharma Q4 net profit rises 16.56 percent to Rs 123 crore

      Garima21 May 2019 9:30 AM IST
      The company had posted a net profit of Rs 105.55 crore for the corresponding period of the previous fiscal, GSK said in a filing to the BSE.New Delhi:...
      Patent Infringement: AstraZeneca moves court against Aurobindo Pharma on generic version of Daliresp

      Patent Infringement: AstraZeneca moves court against Aurobindo Pharma on generic version of Daliresp

      Garima20 May 2019 9:45 AM IST
      Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups or...
      Fortis Healthcare International to sell entire stake in MSCL

      Fortis Healthcare International to sell entire stake in MSCL

      Garima19 May 2019 10:00 AM IST
      Mauritius-based Fortis Healthcare International holds 28.89 per cent stake in Medical and Surgical Centre Ltd (MSCL).New Delhi: Fortis Healthcare...
      Jubilant Life Sciences posts net loss of Rs 100.65 crore in Q4

      Jubilant Life Sciences posts net loss of Rs 100.65 crore in Q4

      Garima19 May 2019 9:30 AM IST
      Jubilant Life Sciences said its bottom line in the quarter was hit by a one-time loan settlement with IFC, that resulted in an exceptional item of Rs...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok